Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Medical Genetics · Familial Non-Medullary Thyroid Cancer

Syndromic vs. Non-Syndromic Thyroid Cancer

At a Glance

Most familial non-medullary thyroid cancer is non-syndromic, so no single genetic test can explain every family. Genetic counseling can identify signs of Cowden syndrome, FAP, DICER1 syndrome, or Carney complex, while a negative test does not erase inherited risk.

When thyroid cancer runs in a family, it is natural to want a single genetic test that can explain why. However, Familial Non-Medullary Thyroid Cancer (FNMTC) is complex. Doctors divide these cases into two main groups: Syndromic, where thyroid cancer is one of many symptoms, and Non-Syndromic, where thyroid cancer is the primary or only concern [1][2].

Syndromic FNMTC: Part of a Larger Picture

In a small minority of familial cases, thyroid cancer is a “red flag” for a broader genetic syndrome [1]. These syndromes are caused by known genetic mutations that increase the risk for several different types of tumors throughout the body.

The most common syndromes include:

  • Cowden Syndrome (PTEN Hamartoma Tumor Syndrome): Caused by mutations in the PTEN gene [3]. It is linked to a higher risk of breast, endometrial (uterine), kidney, and colorectal cancers, as well as skin growths called hamartomas [4][5].
  • Familial Adenomatous Polyposis (FAP) / Gardner Syndrome: Caused by mutations in the APC gene [6]. While primarily known for causing hundreds or thousands of colon polyps and a very high risk of colon cancer, it is also linked to a specific type of thyroid cancer called cribriform-morular papillary thyroid carcinoma [6][7].
  • DICER1 Syndrome: Caused by the DICER1 gene, this syndrome can lead to thyroid issues like multinodular goiter and cancer, alongside rare tumors of the lungs (pleuropulmonary blastoma), kidneys, and ovaries [8][9].
  • Carney Complex: A very rare condition (often linked to the PRKAR1A gene) that features skin “freckling” (lentigines), heart or skin growths (myxomas), and various endocrine tumors, including thyroid cancer [10][11].

For these syndromic forms, referral for genetic counseling and syndrome-directed testing is highly reliable when indicated [12]. Identifying a syndrome is vital because it allows your doctors to set up life-saving screening for other organs, like the colon or breasts [13][7].

Non-Syndromic FNMTC: The Search for Answers

The vast majority of families have non-syndromic FNMTC, meaning thyroid cancer is the only inherited health issue identified [14]. Unlike the syndromes listed above, there is currently no universal genetic test for non-syndromic FNMTC [15][16].

You may see certain genes mentioned in research or on commercial testing panels, but they are not yet considered “diagnostic”:

  • HABP2: Early research suggested this gene might be a cause, but later studies found the variant was common in healthy people and did not consistently track with cancer in many families [17][18].
  • FOXE1: This gene is a “low-penetrance” variant, meaning it might slightly increase your risk, but it doesn’t “cause” the cancer on its own the way a syndrome gene does [19][20].
  • SRGAP1: This remains a “candidate gene” that scientists are still studying; it is not yet proven enough for routine medical use [21].
  • Variants of Uncertain Significance (VUS): Sometimes a panel returns a VUS. These should not be used to guide surgery or screening decisions.

Why is there no single test?

Non-syndromic FNMTC is genetically heterogeneous, which means it isn’t caused by one single “glitch” in everyone [2]. Different families may have different genetic drivers, or the cancer may be caused by a combination of many small genetic factors and shared environmental influences [22][20].

What a “Negative” Test Means

It is crucial to understand that a negative or uninformative genetic panel does not eliminate your familial risk. A negative test only means you likely don’t have the specific broad syndromes tested for. You may still have an inherited susceptibility.

What This Means for You

Because there is no “yes or no” genetic test for most families, doctors manage non-syndromic FNMTC based on your family history and clinical findings [23].

  1. Systematic Assessment: Your doctor should record a detailed “pedigree” (family tree) covering at least three generations to look for patterns [23][16].
  2. Syndrome Screening: If your family history hints at a syndrome (like early-onset colon cancer or specific skin bumps), you should be referred for targeted genetic testing for genes like PTEN or APC [16][12].
  3. Clinical Monitoring: If no syndrome is found, your care will focus on monitoring the thyroid itself. In families with three or more affected members, your doctor may be more proactive about screening or surgical decisions [24][25].

Common questions in this guide

How are syndromic and non-syndromic familial thyroid cancer different?
Syndromic familial non-medullary thyroid cancer is part of an inherited condition that may also cause other cancers or distinctive physical findings. In non-syndromic familial thyroid cancer, thyroid cancer is the main inherited concern, and no single genetic test reliably explains every family.
What inherited syndromes are linked to familial thyroid cancer?
Cowden syndrome, caused by PTEN changes, can raise the risk of thyroid, breast, uterine, kidney, and colorectal cancers. FAP or Gardner syndrome, DICER1 syndrome, and Carney complex can also involve thyroid cancer along with other tumors or characteristic findings. A genetic counselor can help determine whether targeted testing is appropriate.
Should I see a genetic counselor if thyroid cancer runs in my family?
Genetic counseling can be useful when several relatives have thyroid cancer or when the family also has early cancers, many colon polyps, unusual skin growths, lentigines, or myxomas. A counselor can build a three-generation family history and decide whether syndrome-directed testing is warranted.
Does a negative genetic test rule out inherited thyroid cancer risk?
No. A negative or uninformative panel usually means that the specific syndromes or genetic changes tested were not found; it does not eliminate a familial susceptibility that has not yet been identified. Doctors may still base monitoring on your family history and clinical findings.
What does a VUS mean for my thyroid cancer care?
A variant of uncertain significance, or VUS, is a genetic change whose connection to disease is not yet known. It is not a confirmed cause of familial thyroid cancer and should not, by itself, guide surgery or cancer screening. Your genetics team can put the result in context with your family history and current research.
Does cribriform-morular papillary thyroid carcinoma suggest a need for genetic testing?
This thyroid cancer pattern is linked to familial adenomatous polyposis, an APC-related condition that causes numerous colon polyps and increases colon cancer risk. Its presence should prompt a discussion with a genetic counselor or doctor about targeted evaluation, especially if the family has colon polyps or early colon cancer.

Get notified when new evidence is published on Familial papillary or follicular thyroid carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (25)
  1. 1

    Familial non-medullary thyroid carcinoma: clinico-pathological features, current knowledge and novelty regarding genetic risk factors.

    Cirello V

    Minerva endocrinology 2021; (46(1)):5-20 doi:10.23736/S2724-6507.20.03338-6.

    PMID: 33045820
  2. 2

    An update on familial nonmedullary thyroid cancer.

    Ammar SA, Alobuia WM, Kebebew E

    Endocrine 2020; (68(3)):502-507 doi:10.1007/s12020-020-02250-3.

    PMID: 32162184
  3. 3

    PTEN, DICER1, FH, and Their Associated Tumor Susceptibility Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood.

    Schultz KAP, Rednam SP, Kamihara J, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2017; (23(12)):e76-e82 doi:10.1158/1078-0432.CCR-17-0629.

    PMID: 28620008
  4. 4

    ERN GENTURIS cancer surveillance guideline for individuals with PTEN hamartoma tumour syndrome (PHTS).

    Hoogerbrugge N, Blatnik A, Lautrup CK, et al.

    European journal of human genetics : EJHG 2026; doi:10.1038/s41431-026-02181-z.

    PMID: 42463809
  5. 5

    A review on age-related cancer risks in PTEN hamartoma tumor syndrome.

    Hendricks LAJ, Hoogerbrugge N, Schuurs-Hoeijmakers JHM, Vos JR

    Clinical genetics 2021; (99(2)):219-225 doi:10.1111/cge.13875.

    PMID: 33140411
  6. 6

    Cribiform variant of papillary thyroid cancer and familial adenomatous polyposis.

    Perea Del Pozo E, Ramirez Plaza C, Padillo Ruiz J, Martos Martínez JM

    International journal of surgery case reports 2015; (16()):192-4.

    PMID: 26521198
  7. 7

    The genetic puzzle of FAP: exploring novel diagnostic approaches for APC/MUTYH-negative case.

    Grot N, Kazimierczyk M, Szuman M, et al.

    Hereditary cancer in clinical practice 2025; (23(1)):25 doi:10.1186/s13053-025-00318-7.

    PMID: 41204315
  8. 8

    Quantification of Thyroid Cancer and Multinodular Goiter Risk in the DICER1 Syndrome: A Family-Based Cohort Study.

    Khan NE, Bauer AJ, Schultz KAP, et al.

    The Journal of clinical endocrinology and metabolism 2017; (102(5)):1614-1622 doi:10.1210/jc.2016-2954.

    PMID: 28323992
  9. 9

    Update on Pediatric Surveillance Recommendations for PTEN Hamartoma Tumor Syndrome, DICER1-Related Tumor Predisposition, and Tuberous Sclerosis Complex.

    Schultz KAP, MacFarland SP, Perrino MR, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2025; (31(2)):234-244 doi:10.1158/1078-0432.CCR-24-1947.

    PMID: 39540884
  10. 10

    Dermatological and endocrine elements in Carney complex (Review).

    Sandru F, Dumitrascu MC, Petca A, et al.

    Experimental and therapeutic medicine 2021; (22(5)):1313 doi:10.3892/etm.2021.10748.

    PMID: 34630667
  11. 11

    Dermatologic Features of Endocrine Tumor Syndromes-Systematic Review and Meta-Analysis.

    Pálla S, Metyovinyi Z, Meznerics FA, et al.

    International journal of dermatology 2026; (65(3)):464-488 doi:10.1111/ijd.70118.

    PMID: 41165034
  12. 12

    Unmasking familial follicular cell-derived thyroid neoplasms associated with syndromes: DICER1 and PTEN-hamartoma tumor syndromes.

    Riascos MC, Agaimy A, Nosé V

    Virchows Archiv : an international journal of pathology 2026; (488(1)):147-157 doi:10.1007/s00428-025-04384-z.

    PMID: 41483301
  13. 13

    Cancer and Overgrowth Manifestations of PTEN Hamartoma Tumor Syndrome: Management Recommendations from the International PHTS Consensus Guidelines Working Group.

    Dhawan A, Baitamouni S, Liu D, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2025; (31(9)):1754-1765 doi:10.1158/1078-0432.CCR-24-3819.

    PMID: 39937242
  14. 14

    Familial non medullary thyroid carcinoma: Beyond the syndromic forms.

    Orois A, Mora M, Halperin I, Oriola J

    Endocrinologia, diabetes y nutricion 2021; (68(4)):260-269 doi:10.1016/j.endinu.2020.08.002.

    PMID: 33191196
  15. 15

    Chromosomal localization of mutated genes in non-syndromic familial thyroid cancer.

    Jiang YJ, Xia Y, Han ZJ, et al.

    Frontiers in oncology 2024; (14()):1286426 doi:10.3389/fonc.2024.1286426.

    PMID: 38571492
  16. 16

    Familial non-medullary thyroid cancer: unraveling the genetic maze.

    Peiling Yang S, Ngeow J

    Endocrine-related cancer 2016; (23(12)):R577-R595 doi:10.1530/ERC-16-0067.

    PMID: 27807061
  17. 17

    HABP2 germline variants are uncommon in familial nonmedullary thyroid cancer.

    Weeks AL, Wilson SG, Ward L, et al.

    BMC medical genetics 2016; (17(1)):60 doi:10.1186/s12881-016-0323-1.

    PMID: 27530615
  18. 18

    HABP2 G534E Variant in Papillary Thyroid Carcinoma.

    Tomsic J, Fultz R, Liyanarachchi S, et al.

    PloS one 2016; (11(1)):e0146315 doi:10.1371/journal.pone.0146315.

    PMID: 26745718
  19. 19

    Genotype Analyses in the Japanese and Belarusian Populations Reveal Independent Effects of rs965513 and rs1867277 but Do Not Support the Role of FOXE1 Polyalanine Tract Length in Conferring Risk for Papillary Thyroid Carcinoma.

    Nikitski AV, Rogounovitch TI, Bychkov A, et al.

    Thyroid : official journal of the American Thyroid Association 2017; (27(2)):224-235 doi:10.1089/thy.2015.0541.

    PMID: 27824288
  20. 20

    Genome-wide association and expression quantitative trait loci studies identify multiple susceptibility loci for thyroid cancer.

    Son HY, Hwangbo Y, Yoo SK, et al.

    Nature communications 2017; (8()):15966 doi:10.1038/ncomms15966.

    PMID: 28703219
  21. 21

    Familial nonmedullary thyroid cancer: a case series in Iranian patients with a meta-review of case series.

    Mohammadi Zaniani Z, Zeinalian M, Tabatabaiefar MA

    Laboratory medicine 2024; (55(4)):506-516 doi:10.1093/labmed/lmad098.

    PMID: 38007399
  22. 22

    BROX haploinsufficiency in familial nonmedullary thyroid cancer.

    Pasquali D, Torella A, Accardo G, et al.

    Journal of endocrinological investigation 2021; (44(1)):165-171 doi:10.1007/s40618-020-01286-6.

    PMID: 32385852
  23. 23

    The impact of family history on non-medullary thyroid cancer.

    Nixon IJ, Suárez C, Simo R, et al.

    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2016; (42(10)):1455-63.

    PMID: 27561845
  24. 24

    Relationship between affected family members and clinical aggressiveness in Familial non-medullary thyroid carcinoma: a systematic review and meta-analysis.

    Yang G, Tian Y, Zhang Y, et al.

    Endocrine 2025; (90(3)):1149-1167 doi:10.1007/s12020-025-04413-6.

    PMID: 40908394
  25. 25

    Results of Screening in Familial Non-Medullary Thyroid Cancer.

    Klubo-Gwiezdzinska J, Yang L, Merkel R, et al.

    Thyroid : official journal of the American Thyroid Association 2017; (27(8)):1017-1024 doi:10.1089/thy.2016.0668.

    PMID: 28657510

This page explains inherited patterns and genetic testing in familial non-medullary thyroid cancer for informational purposes only and does not constitute medical advice. A genetic counselor and your thyroid care team should interpret your family history and test results before screening or treatment decisions.

Guide contents Familial papillary or follicular thyroid carcinoma
Research & Literature
01 Understanding Familial Non-Medullary Thyroid Cancer (FNMTC) 03 How FNMTC Behaves